Viral Vector– tag –
-
Northway Biotech Unveils €61M Lithuanian Facility to Industrialize CAR-T, Integrating Vector Supply for Next-Gen Therapies
Invest Lithuania Lithuania Overview Northway Biotech has inaugurated a €61 million, 3,500 sq. meter CDMO facility in Vilnius, Lithuania, designed to industrialize the manufacturing of allogeneic CAR-T and other advanced cell and gene the... -
Scaling Viral Vector Manufacturing: The Bottleneck to Gene Therapy’s Broader Impact
Cytiva International Overview As gene therapies expand their application beyond rare diseases, the industry faces an urgent need for efficient, consistent, and large-scale viral vector manufacturing. This demand necessitates comprehensiv... -
Viral Vector Packaging Services Market Signals Rapid Growth Driven by Gene Therapy Commercialization and Increased Biomanufacturing Investment
openPR.com USA Overview This article provides an overview of a market research report from openPR.com. The global viral vector packaging services market is experiencing rapid growth, driven by advancing gene therapy commercialization and... -
Huazhong University of Science and Technology Tongji Hospital Demonstrates In Vivo CAR-T Therapy, Achieving Cost Reduction and Immune Reset for Multiple Sclerosis
Chosunbiz South Korea Overview A research team at Huazhong University of Science and Technology Tongji Hospital has demonstrated in vivo CAR-T therapy for autoimmune diseases like multiple sclerosis, successfully reducing manufacturing a... -
CDMO Signal Ranks Viral Vector CDMOs: Thermo Fisher Scientific, AGC Biologics, and Takeda Lead Top Tier
CDMO Signal USA Overview CDMO Signal released its latest ranking of viral vector CDMOs, including AAV, lentiviral, and adenoviral modalities. Thermo Fisher Scientific, AGC Biologics, and Takeda secured top positions in the overall Signal... -
Winship Cancer Institute Launches Cellular Therapy Initiative, Expanding GMP Manufacturing Capacity for Next-Generation Cancer Treatments
Winship Cancer Institute USA Overview The Winship Cancer Institute has launched a Cellular Therapy Initiative to accelerate the development of next-generation cancer treatments. This initiative significantly expands GMP manufacturing cap... -
AGC Biologics Highlights Strengths as Global CDMO Partner for Biologics and Advanced Therapies
The Economy Global Overview AGC Biologics is recognized as a global biopharmaceutical CDMO providing development and manufacturing services across a wide range of advanced modalities, including biologics, plasmid DNA, mRNA, viral vectors... -
ProBio Establishes Cell and Gene Therapy CDMO Center of Excellence in Hopewell, New Jersey, Specializing in Plasmid DNA and Viral Vector Manufacturing
ProBio USA Overview ProBio has opened a Cell and Gene Therapy Center of Excellence in Hopewell, New Jersey, focusing on the development and GMP manufacturing of plasmid DNA and viral vectors. This new facility is designed to meet stringe... -
Precision BioSciences Initiates Clinical Trial for ARCUS Nuclease Gene Editing Therapy PBGENE-DMD in DMD
CRISPR Medicine News USA Overview Precision BioSciences has dosed the first patient in its Phase 1/2 clinical trial for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy (DMD). This therapy utilizes two ARCUS nucleases t... -
CRISPR-Cas9 Breakthrough: CTX310 Delivers Sustained Lipid Control for Dyslipidemia in Phase 1a Trial, Published in NEJM
The New England Journal of Medicine USA Overview CRISPR Therapeutics' CTX310, a novel CRISPR-Cas9 gene-editing therapy, has demonstrated sustained and profound reductions in key lipid markers—angiopoietin-like 3 (ANGPTL3), triglycerides,...
